Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effective Dose of Taigilidine + Propofol for Suppressing Cervical Dilation Response During Hysteroscopy
ChiCTR2600122160Phase 4Recruiting
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tigloidine in intrauterine space-occupying lesion (IUSOL) (2 arms), sponsored by Zhongshan Hospital (Xiamen), Fudan University. Primary endpoint: Effective Dose (ED) of Taigilidine for Cervical Dilation Response Suppression. Started Apr 2026; status: recruiting.
02
Drugs
tigloidine
03
Conditions
intrauterine space-occupying lesion (IUSOL)
Beyond the preview
Go deeper on ChiCTR2600122160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122160.